# US 2022/0090998 A1 · Urine stabilization

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0090998 A1
- Document ID: US20220090998A1
- Status: Published application
- Kind: A1
- Application number: 17/416,814
- Filed: 2020-01-02
- Published: 2022-03-24
- Earliest claimed: 2019-01-04
- Assignees: Qiagen GmbH
- Applicants: QIAGEN GmbH
- Inventors: Daniel GRÖLZ
- Web page: https://patentgrep.com/patent/US20220090998A1

## CPC

- G01N 1/34: Purifying; Cleaning {(processes or apparatus for extracting or separating nucleic acids from biological samples C12N15/1003)}
- A01N 31/02: Acyclic compounds
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- G01N 1/30: Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis}
- A61B 10/007: {for taking urine samples (measuring urological functions A61B5/20; genital receptacles A61F5/451; urinals for bed-ridden persons A61G9/006)}
- A61B 10/0096: {Casings for storing test samples (A61B10/0038, A61B10/0045 take precedence; preservation of living parts of the human or animal body A01N1/10; containers for retaining a material to be analysed B01L3/50; containers for enzymology or microbiology C12M1/16; swab-sampler being part of enzymology or microbiology container C12M1/30)}
- A61F 5/451: Genital {or anal} receptacles (A61F5/441, A61F5/442, A61F5/443 take precedence {; other body securing means A61F5/4408; devices for taking faeces samples A61B10/0038; devices for taking urine samples A61B10/007})
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

The present disclosure provides a method for stabilizing a urine sample comprising contacting the urine sample for stabilization with EDTA, at least one poly(oxyethylene) polymer and a preservative for inhibiting bacterial growth. Also provided are stabilizing compositions and methods for processing stabilized urine sample.

## Claims

### Claim 1

A method for stabilizing a urine sample comprising:
a) contacting the urine sample for stabilization with a chelating agent and at least one poly(oxyethylene) polymer, wherein bacterial growth is inhibited in the stabilized urine sample.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the urine sample is further contacted with a preservative for inhibiting bacterial growth.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the chelating agent is EDTA.

### Claim 4 (depends on 1)

The method according to claim 1, comprising contacting the urine sample with a stabilizing composition which comprises the chelating agent, preferably EDTA, and the poly(oxyethylene) polymer, preferably polyethylene glycol, and optionally a preservative for inhibiting bacterial growth.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the stabilizing composition comprises a buffering agent and has a pH in the range of >7 to 9.5, such as 7.2 to 9.5, 7.3 to 9.5, 7.4 to 9.5 or 7.5 to 9.5.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the stabilizing composition is contacted with the urine sample in a volumetric ratio selected from 1:3 to 1:10, preferably 1:5 to 1:8.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the pH of the stabilized urine sample lies in a range of 6 to 9.5, such as 6.3 to 9.5, 6.5 to 9.5, 6.7 to 9, 7 to 9, or 7.2 to 9.

### Claim 8 (depends on 3)

The method according to claim 3, having one or more of the following characteristics:
(i) wherein in the stabilized urine sample, the final concentration of EDTA lies in a range of 2 mg/ml to 40 mg/ml, preferably 10 mg/ml to 30 mg/ml;
(ii) the method comprises contacting the urine sample with a stabilizing composition that comprises EDTA in a final concentration that lies in a range of 100 mM up to the solubility limit, preferably 150 mM to 500 mM.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the at least one poly(oxyethylene) polymer is a polyethylene glycol.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the urine sample is contacted with a high molecular weight poly(oxyethylene) polymer having a molecular weight of at least 1500 and a low molecular weight poly(oxyethylene) having a molecular weight of 1000 or less, and wherein preferably these polymers are comprised in the stabilization composition that additionally comprises the chelating agent, preferably EDTA, and optionally a preservative for inhibiting bacterial growth.

### Claim 11 (depends on 2)

The method according to claim 2, wherein the preservative for inhibiting bacterial growth is a preservative that has one or more of the following characteristics:
(a) it is an antimicrobial and preferably has antibacterial and antifungal effects,
(b) the preservative comprises or consists of a chemical compound or two or more chemical compounds,
(c) the preservative comprises or consists of sodium azide,
(d) the preservative comprises at least one isothiazolinone compound, preferably methylchloroisothiazolinone and/or methylisothiazolinone;
(e) the preservative comprises chlorhexidine; and
(f) the preservative comprises sodium borate.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the urine sample is additionally contacted with at least one caspase inhibitor and wherein preferably, the caspase inhibitor is comprised in a stabilizing composition that comprises the chelating agent, preferably EDTA, and the poly(oxyethylene) polymer, preferably polyethylene glycol, and optionally a preservative, for inhibiting bacterial growth.

### Claim 13 (depends on 4)

The method according to claim 4, wherein the stabilizing composition comprises:
EDTA,
at least one polyethylene glycol, preferably at least one high molecular weight polyethylene glycol having a molecular weight of at least 3000 and optionally at least one low molecular weight polyethylene glycol having a molecular weight of 1000 or less,
a preservative for inhibiting bacterial growth,
a buffering agent,
at least one caspase inhibitor, and
optionally at least one primary, secondary or tertiary amide.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the stabilizing composition is a liquid composition comprising
EDTA in a concentration of 100 mM up to the solubility limit, preferably 150 mM to 500 mM,
at least one polyethylene glycol, preferably at least one high molecular weight polyethylene glycol having a molecular weight of at least 6000 and optionally at least one low molecular weight polyethylene glycol having a molecular weight of 1000 or less,
a preservative for inhibiting bacterial growth,
a buffering agent,
at least one caspase inhibitor, and
optionally at least one primary, secondary or tertiary amide,
wherein the pH of the stabilizing composition is lies in the range of >7 to 9.5, and wherein the stabilizing composition is contacted with the urine sample in a volumetric ratio selected from 1:3 to 1:10, preferably 1:5 to 1:8.

### Claim 15 (depends on 4)

The method according to claim 4, wherein the stabilizing composition has one or more of the following characteristics:
i) the stabilizing composition stabilizes extracellular DNA comprised in the urine sample against degradation; and
ii) the stabilizing composition stabilizes cytology of exfoliated, nucleated cells in the urine sample, genomic DNA within the nucleated cells and extracellular DNA in the urine sample.

### Claim 16 (depends on 1)

The method according to claim 1, further comprising:
b) processing the stabilized urine sample by separating cells from the stabilized urine sample, thereby providing (i) a cell sample and (ii) a cell-depleted supernatant.

### Claim 17 (depends on 16)

The method according to claim 16, further comprising
c) purifying extracellular DNA from the cell-depleted supernatant;
d) purifying genomic DNA from the obtained cell sample, and/or
e) preparing exfoliated cells for cytology from the obtained cell sample.

### Claim 18

A stabilizing composition for stabilizing a urine sample wherein bacterial growth is inhibited in the stabilized urine sample, the composition comprising
a chelating agent, preferably EDTA,
at least one poly(oxyethylene) polymer, and optionally
a preservative for inhibiting bacterial growth.

### Claim at position 19

-24. (canceled)

### Claim 25

A reception device for receiving a urine sample, wherein the reception device comprises
a chelating agent, preferably EDTA,
at least one poly(oxyethylene) polymer, preferably polyethylene glycol, and
optionally a preservative for inhibiting bacterial growth.

### Claim at position 21

-30. (canceled)

### Claim 31 (depends on 1)

The method according to claim 1, further comprising
x) collecting urine in a container, preferably a urine cup, before step a).

### Claim 32 (depends on 31)

The method according to claim 31, comprising transferring the urine collected in step x) for stabilization in step a) into a reception device that comprises:
a chelating agent, preferably EDTA,
at least one poly(oxyethylene) polymer, preferably polyethylene glycol, and
optionally a preservative for inhibiting bacterial growth.

### Claim 33 (depends on 31)

The method according to claim 31, wherein the container used in step x) comprises one or more stabilizing agents in dry form, preferably spray-dried form.

### Claim 34 (depends on 33)

The method according to claim 33, wherein the container used in step x) comprises a chelating agent, such as preferably EDTA.

### Claim 35 (depends on 31)

The method according to claim 31, wherein after stabilization in step a), the stabilized urine sample is further processed by b) separating cells from the stabilized urine sample, thereby providing (i) a cell sample and (ii) a cell-depleted supernatant, optionally wherein the method further comprises one or more of c) (i) purifying extracellular DNA from the cell-depleted supernatant, c) (ii) purifying genomic DNA from the obtained cell sample, and c) (iii) preparing exfoliated cells for cytology from the obtained cell sample.
